SXSW 2025
Microdosing DEI: Equity in Psychedelics
Description:
Join us for a thought-provoking discussion on the crucial topic of equity within the emerging psychedelics industry. This session will examine how disparities in the industry impact access, representation, and outcomes for marginalized communities. Our expert panelists will explore the historical context of these inequities, highlighting the barriers that have prevented diverse voices from contributing to and benefiting from psychedelic research. We will discuss the ethical considerations and necessary steps to ensure that the expansion of psychedelic therapies is inclusive and just.
Other Resources / Information
Harvard Law: Bill of Health – “Psychedelic Inequities and Unexplored Risk”
https://blog.petrieflom.law.harvard.edu/2024/02/27/psychedelic-inequities-and-unexplored-risk-colonization-commercialization-and-regulation/
Takeaways
- Examining the importance of representation in health and wellness research.
- Advancing the narrative on psychedelics and their healing value among underrepresented communities.
- Discuss the ethical considerations and what must happen for the psychedelic industry to have a more inclusive future.
Speakers
- Gena Pemberton, Chief Diversity, Equity & Inclusion Officer, Omnicom Health Group
- Paulette Johnson, EVP, Digital Growth and Operations, Harrison & Star
- Shaakira Haywood Stewart, PhD, Founder, DR. SHAAKIRA HAYWOOD STEWART PSYCHOLOGY, P.C.
Organizer
Ana Leen, Director, DEI, Omnicom Group
SXSW reserves the right to restrict access to or availability of comments related to PanelPicker proposals that it considers objectionable.
Add Comments